Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Francesca Rastelli

Showing results (21-30 of 37) with videos related to

Pageof 4
Sort By:
Journal for Immunotherapy of Cancer|November 6, 2020
Integrated analysis of concomitant medications and oncological outcomes from PD-1/PD-L1 checkpoint inhibitors in clinical practiceAlessio Cortellini, Marco Tucci, Vincenzo Adamo, et al.
Tumori|May 4, 2026
Outcomes of first-line chemo-immunotherapy in advanced non-squamous NSCLC according to <i>KRAS</i> status: An Italian real-world studyAlessandro Leonetti, Vanessa Callegari, Fabiana Perrone, et al.
European Journal of Cancer (Oxford, England : 1990)|March 15, 2024
Real-world outcomes of Italian patients with advanced non-squamous lung cancer treated with first-line pembrolizumab plus platinum-pemetrexedAlessandro Leonetti, Fabiana Perrone, Matteo Puntoni, et al.
European Journal of Cancer (Oxford, England : 1990)|June 27, 2026
Corrigendum to "Real-world outcomes of Italian patients with advanced non-squamous lung cancer treated with first-line pembrolizumab plus platinum-pemetrexed" [Eur J Cancer 202, May 2024, 114006]Alessandro Leonetti, Fabiana Perrone, Matteo Puntoni, et al.
Journal for Immunotherapy of Cancer|March 1, 2019
A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorableAlessio Cortellini, Melissa Bersanelli, Sebastiano Buti, et al.
Journal for Immunotherapy of Cancer|October 20, 2020
Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression ≥ 50%: a multicenter study with external validationAlessio Cortellini, Biagio Ricciuti, Marcello Tiseo, et al.
Journal of Hematology & Oncology|January 22, 2022
High familial burden of cancer correlates with improved outcome from immunotherapy in patients with NSCLC independent of somatic DNA damage response gene statusAlessio Cortellini, Raffaele Giusti, Marco Filetti, et al.
European Journal of Cancer (Oxford, England : 1990)|November 19, 2020
Effect of concomitant medications with immune-modulatory properties on the outcomes of patients with advanced cancer treated with immune checkpoint inhibitors: development and validation of a novel prognostic indexSebastiano Buti, Melissa Bersanelli, Fabiana Perrone, et al.
Oncoimmunology|February 1, 2020
Evaluating the role of FAMIly history of cancer and diagnosis of multiple neoplasms in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: the multicenter FAMI-L1 studyAlessio Cortellini, Sebastiano Buti, Melissa Bersanelli, et al.
Journal of Translational Medicine|June 25, 2021
PD-1/PD-L1 checkpoint inhibitors during late stages of life: an ad-hoc analysis from a large multicenter cohortDaniele Santini, Tea Zeppola, Marco Russano, et al.
Pageof 4

Showing results (21-30 of 37) with videos related to

Sort By:
Pageof 4
Journal for Immunotherapy of Cancer|November 6, 2020
Integrated analysis of concomitant medications and oncological outcomes from PD-1/PD-L1 checkpoint inhibitors in clinical practiceAlessio Cortellini, Marco Tucci, Vincenzo Adamo, et al.
Tumori|May 4, 2026
Outcomes of first-line chemo-immunotherapy in advanced non-squamous NSCLC according to <i>KRAS</i> status: An Italian real-world studyAlessandro Leonetti, Vanessa Callegari, Fabiana Perrone, et al.
European Journal of Cancer (Oxford, England : 1990)|March 15, 2024
Real-world outcomes of Italian patients with advanced non-squamous lung cancer treated with first-line pembrolizumab plus platinum-pemetrexedAlessandro Leonetti, Fabiana Perrone, Matteo Puntoni, et al.
European Journal of Cancer (Oxford, England : 1990)|June 27, 2026
Corrigendum to "Real-world outcomes of Italian patients with advanced non-squamous lung cancer treated with first-line pembrolizumab plus platinum-pemetrexed" [Eur J Cancer 202, May 2024, 114006]Alessandro Leonetti, Fabiana Perrone, Matteo Puntoni, et al.
Journal for Immunotherapy of Cancer|March 1, 2019
A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorableAlessio Cortellini, Melissa Bersanelli, Sebastiano Buti, et al.
Journal for Immunotherapy of Cancer|October 20, 2020
Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression ≥ 50%: a multicenter study with external validationAlessio Cortellini, Biagio Ricciuti, Marcello Tiseo, et al.
Journal of Hematology & Oncology|January 22, 2022
High familial burden of cancer correlates with improved outcome from immunotherapy in patients with NSCLC independent of somatic DNA damage response gene statusAlessio Cortellini, Raffaele Giusti, Marco Filetti, et al.
European Journal of Cancer (Oxford, England : 1990)|November 19, 2020
Effect of concomitant medications with immune-modulatory properties on the outcomes of patients with advanced cancer treated with immune checkpoint inhibitors: development and validation of a novel prognostic indexSebastiano Buti, Melissa Bersanelli, Fabiana Perrone, et al.
Oncoimmunology|February 1, 2020
Evaluating the role of FAMIly history of cancer and diagnosis of multiple neoplasms in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: the multicenter FAMI-L1 studyAlessio Cortellini, Sebastiano Buti, Melissa Bersanelli, et al.
Journal of Translational Medicine|June 25, 2021
PD-1/PD-L1 checkpoint inhibitors during late stages of life: an ad-hoc analysis from a large multicenter cohortDaniele Santini, Tea Zeppola, Marco Russano, et al.
Pageof 4